Because melanoma patients commonly harbor genetic alterations in BRAF, NRAS, CDKN2A, or NF1 genes that contribute to tumor progression10–13, we examined potential associations between these genetic alterations and IRAK-M levels in melanoma cell lines and patient samples. This evidence concerns the gene CDKN2A and neoplasm.